CartiHeal secures $5M in venture funding CartiHeal.

The capability to regenerate hyaline cartilage, rather than ‘hyaline-like cartilage, in a single stage procedure, without the use of exogenous cells or growth factors, is considered the Holy Grail in cartilage restoration. The Agili-CTM can be CE marked and the business happens to be running post-marketing clinical research at leading centers in European countries and Israel. Related StoriesImproved outcomes yielded from new ChIP-seq protocolLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. KlegermanLinkam phases used in the Wolfson Bioimaging Facility at the University of Bristol as part of the endocytic sorting research of Dr Paul VerkadeThere are around 1.2 million cartilage repair methods performed world-wide annually, according to BioMedGPS.Beneath the agreement, Pfizer can make an upfront payment of $250 million to AstraZeneca, and AstraZeneca is normally eligible to receive milestone and royalty obligations predicated on product launches and product sales. NEXIUM, a Proton Pump Inhibitor premiered by AstraZeneca in European countries in 2000 and the U.S. In 2001. AstraZeneca shall continue steadily to manufacture and market the prescription item, as well as source Pfizer with the OTC item upon the receipt of regulatory acceptance. A Marketing Authorisation Software for OTC NEXIUM in a 20mg tablet form was filed with the European Medications Agency in June 2012.